BioSpace News Archive

Innovative system measures stomach motility to help clinicians identify enteral feeding intolerance Technology designed to help address malnutrition in the ICU and support clinical decision-making Baxter gains exclusive distribution rights to bring system to clinicians worldwide

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced the company will release second quarter 2020 financial results on Wednesday, August 5, 2020 after the close of market. Lyra will host a corresponding conference call and live webc

Unicity International, a leader in metabolic health solutions, has been issued a US patent for an innovative process in its OmegaLife-3 Resolv supplement: US Pat. No. 10,624,907 B2. Unicity Int

LifeLabs is pleased to share that it has been selected as the medical laboratory partner for the NHL’s Return to Play Plan as part of LifeLabs’ WorkClear program, an evidence-based approach to help companies bring employees safely back to work.

Dr. Arthur Castelbaum of RMA Philadelphia joins leadership developing best practice protocols for diagnosing and treating infertile couples.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities purchase agreement for the sale of common units and prefunded warrant units, as described below, in a private placement with certain institutional and other accredited investors for gross

The DNA polymerases refer to those enzymes that generate DNA molecules through assembling of nucleotides.

Lysogene, a Phase 3 gene therapy platform company targeting central nervous system diseases, provides H1 2020 Business update.

Calliditas Therapeutics AB announced that it has reorganized its management team.

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today released a statement on the July 23rd U.S. Patent Trial and Appeal Board (PTAB) ruling: